Futura Medical Share Discussion Threads

[glavey] 09/7/2025 04:43:14

¯¬_(ツ)_/¯

[kinwah] 08/7/2025 09:38:44

I think Duggan has been brought in to prepare the business for sale if possible. First he has to assess what there is of any commercial value. Secondly he will have to slash costs to try and stabilise the cash outflow. The situation could deteriorate very quickly. The promised new products need development spending which the company can't afford to do by itself. He's got a tough job on his hands so I wish him luck!

[jonnybig] 08/7/2025 07:59:09

The beginning of the end imo. I'm guessing barder might have been paid a "generous" severance pay and he's got a shed full of shares to dump.

spud

[takeiteasy] 08/7/2025 07:06:39

Fresh start - what can possibly be retrieved from this mess....the word "should" has been used...rather than "does" which is honest I suspect ....answers on a postcard etc

Alex Duggan, Futura's incoming Interim Chief Executive Officer commented: "I'm pleased to be joining Futura on an interim basis to review the business performance and develop the future strategy. The patented technology behind the Eroxon® brand, along with the pipeline of new products in development, should hold strong potential for broad global consumer appeal. I look forward to reviewing the current commercial plans, results of the initial market launches and working with the team to shape a strategy that maximises value for shareholders, commercial partners, and employees."

[onedayrodders] 23/6/2025 12:32:35

"It's not some super stiffening or enlarging agent sold to enhance male prowess and turn you into a porno stud!!"

That's right Glavey.. in fact the paying public have confirmed it's actually not ANYTHING but a useless irrelevant gel with fake promises.

I'll leave the share price to do the talking

TTFN

[glavey] 23/6/2025 07:54:21

"you don't need to have ED to try it and it should have the same effect"

This must be one of the most daft comments I've read in a while. If you don't have ED then you can get an adequate erection normally, so what notable effect would you expect to experience from a product specifically intended to help ED suffers (and not anyone else) get an adequate erection?! It's not some super stiffening or enlarging agent sold to enhance male prowess and turn you into a porno stud!!

[mdi] 19/6/2025 12:26:05

And an AGM that lasts less then 10 minutes and provides no real positive statements or even provides an opportunity for shareholders questions?

[jonnybig] 11/5/2025 12:29:52

Just imagine how bonkers it would be to sell a placebo pain relief gel or tablets with no active ingredients. So why is it OK to peddle a placebo ED treatment? This is a train crash waiting to happen.

spud

[mdi] 07/5/2025 08:18:43

Eroxon revenues declining in Nordic markets that had already launched so they then launch in Denmark to offload the stock that is building up? Explains the slow phased launches in new territories which is just an attempt at trying to make up for the clearly declining revenues after launch hype fades and consumers realise its just a placebo gel made of alcohol and water. hTtps://finance.yahoo.com/news/navamedic-q1-2025-strong-start-051800751.html The company's third business area, Consumer Health, delivered stable results. Revenues of Modifast were steady during Q1, whilst Absolut Torr (up 49 per cent YoY) and ThermaCare (up 8 per cent YoY) experienced strong growth. Eroxon saw a 9 per cent decrease in revenues, which is explained by a stock build-up in Q1 2024 hTtps://www.tipranks.com/news/company-announcements/navamedic-expands-eroxon-launch-to-denmark-addressing-mens-health-needs

[mdi] 30/4/2025 13:36:38

And now Stifel no longer acting as Futura broker and Haleon don’t even see Eroxon as a product worth mentioning in their Q1 Results statement or presentation hTtps://www.haleon.com/content/dam/haleon/corporate/documents/investors/results/q1-2025/Haleon-q1-2025-trading-statement.pdf.downloadasset.pdfhTtps://www.haleon.com/content/dam/haleon/corporate/documents/investors/results/q1-2025/Haleon-q1-2025-trading-statement-presentation.pdf.downloadasset.pdf

[billthebank] 17/4/2025 08:42:14

What a total crock of poo this is

[mdi] 15/4/2025 11:33:49

I see the CEO saying in the Proactive interview that partners are still committed to Eroxon but he then admits all the agreements had a minimum 3 year commitment clause on partners. Which is slightly worrying as Coopers initial agreement was executed back in May 2022. Could Coopers be about to hand back the Eroxon rights and walk away from May 2025?

[bandflex] 15/4/2025 10:01:31

2024 full year UK and Euro revenue £4778870
2024 H1 UK and Euro revenue £2759280
So H2 revenue fell to £ 2019590 even though it was released in more euro countries.

2024 rest of world full year revenue £1,312,198
2024 H1 rest of world revenue £ 1,014,830
So 2024 H2 rest of world revenue cratered to £ 297368

US launched in 2024 H2 so no comparison for sales revenue only milestone payments.

Sales have clearly fallen towards the end of 2024 and have gotten worse in all markets in 2025, but FUM will hide the figures until the 2025 H1 results sometime in September. So get ready for 5 months of BS from FUM before reality hits.

[mdi] 15/4/2025 09:33:13

Under consumer law consumers are entitled to refunds if they can make a case they were misled by the implied claims Eroxon is 'clinically proven' beyond using any similar placebo Hydroalcoholic gel in a double blind study. Also some Haleon customers on Amazon have said they got refunds.1.0 out of 5 stars Verified PurchaseSCAMReviewed in the United States on October 6, 2024Pure Garbage.....Only + was they gave me refund by chat.hTtps://europa.eu/youreurope/citizens/consumers/unfair-treatment/unfair-commercial-practices/index_en.htm'Refund policies for Eroxon vary based on the retailer, including Amazon and eBay.It's essential to check the specific retailer's refund policy before making a purchase.Some retailers may offer refunds within a certain timeframe after purchase, while others may have more limited return options'hTtps://www.classaction.org/news/class-action-claims-neuriva-makers-have-no-scientific-clinical-proof-supplement-improves-brain-performancecompanies deceptively touted 'clinically proven'Class members with proof of purchase are eligible to recover up to $65. Those without proof may recover up to $20.The companies also agreed to change all references from ˜clinically proven' and 'science proved' on Neuriva labeling and ancillary marketing to ˜clinically tested' and 'science tested' or other similar language.Magistrate Judge Jonathan Goodman of the U.S. District Court for the Southern District of Florida granted preliminary approval April 23.Plaintiffs attorneys will seek up to $2.9 million for fees and expenses. They will also seek incentive awards up to $2,000 each for five class representatives.

[glavey] 15/4/2025 09:26:01

Is an apothecary saddled with unsold stocks of Eroxon reaching their expiry date going to be persuaded to speculate on a better future sales demand for Eroxon Intense?

[kinwah] 15/4/2025 08:52:51

MDI you were right first time there are no refunds to purchasers of Eroxon. Minimum order quantities are common when manufacture is subcontracted because of overhead costs, dedicated facilities etc. Eroxon sales in the current year are well below anticipated levels so FUM's having to pay its supplier penalties for breaching the terms of the contract. Eroxon Intense is FUM's only hope of surviving until the end of the year without raising more cash or selling itself to another healthcare company who might covet that link-up with Haleon and see it as a foot in the door to sell its own products.

[kinwah] 15/4/2025 08:25:13

MDI well done reading through to the end. The provision you picked up is due to FUM not calling off enough manufactured stock from its supplier due to poor demand. The extent of this contractual commitment is unknown but is a big worry. No wonder the auditors were shuffling in their seats.

[kinwah] 15/4/2025 08:13:17

The clues are there. The bulk of the sales come from 'retailer sell-in', i.e. stocking up on launch. Hence the interest in Eroxon Intense which would give FUM another chance of launch sales. The big non-mention in these results is repeat sales to consumers and we know that is because they are so poor. Most men who try it are dissatisfied with the outcome. FUM say targeting those men for whom it works is proving difficult especially as the 'wrong men' like older blokes try it out of interest only to be disappointed. Sadly I think FUM has to put itself up for sale before it runs out of cash.

[mdi] 15/4/2025 08:08:31

Partners do not even want to reorder the contracted minimum order amounts and are instead paying penalties rather then stuck with product that is not selling?Under Going Concern:'In assessing the appropriateness of adopting the going concern assumption, the Group has prepared a detailed budget ("the budget") for the period ending 31 December 2025 and a further forecast ("the forecast") for the period ending 30 June 2026.'Then under Provisions:'At the reporting date, the Group has recognised a provision of £726,948 (2023:£nil) for minimum order penalties under its supply contracts. The provision represents penalties expected to be incurred due to not meeting the agreed-upon minimum order quantities during the financial year. The Group estimates that £286,948 of this provision will be paid within the next 12 months, with the remainder expected to be paid over the following 12 to 24 months.'


And what is this warning? Is there a disagreement with partners on who pays for the customers getting refunds? Are they worried about a class action suit?

« Contracts with customers carry no obligations relating to returns or refunds of the product. As such, no provision has been made in respect of returns or refund »

hTtps://www.medtecheurope.org/medtech-views/policy-views/third-party-litigation-in-europe-could-it-fuel-a-us-style-class-action-culture/